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Abstract.
Background: Multifocal motor neuropathy (MMN) is associated with IgM antibodies to GM1 ganglioside. The importance of
the lipid milieu that might facilitate or inhibit antibody binding to GM1 in immunoassays is well recognised. Existing studies,
using a range of different approaches, generally concur that anti-GM1 IgM antibody detection rates are improved by the addition
of galactocerebroside (GalC) to the GM1 assay.
Objective: The current study sought to formally evaluate the clinical utility of the GM1:GalC complex assay in the diagnosis
of MMN.
Methods: Anti-GM1 and -GM1:GalC antibodies were examined using ELISA and glycoarray (dot blot) in a fully blinded study
design, consisting of 100 MMN patients, 100 ALS cases and 100 healthy controls.
Results: The detection of anti-GM1 Abs using glycoarray was 67% sensitive and 85% specific. The addition of GalC to GM1,
(1:1 weight to weight ratio), increased the sensitivity to 81%, whilst dropping specificity to 80%. Increasing the GalC content
to a 1:5 ratio (or higher) further decreased specificity, and in doing so limited the usefulness of the GM1:GalC assay to the level
of GM1 alone. The addition of GalC to the ELISA method also significantly increased sensitivity compared with GM1 alone,
albeit with a significant decrease in specificity.
Conclusions: This study indicates that the GM1:GalC assay is an advantageous assay adaptation for detecting anti-GM1
antibodies in MMN, using either glycoarray or ELISA, and warrants introduction into clinical diagnostic practice.
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INTRODUCTION
Detection of anti-GM1 IgM antibodies (Abs) is often
used as a clinical tool in the differential diagnosis
of multifocal motor neuropathy (MMN). However,
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optimal assay methodology remains uncertain due to
wide assay sensitivity and specificity variations, both
between and within laboratories [1, 2]. Almost twenty
years have passed since the description of galactocere-
broside (GalC) as one potential binding enhancer of
the anti-GM1 Abs that are present in MMN sera [3].
This original ELISA-based study concluded that the
addition of GalC (and sulphated cholesterol) in tenfold
ratiometric excess of GM1 unmasked Ab reactivi-
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ties in a significant number of MMN patients which
had been previously characterised as anti-GM1 Ab
negative. More recently, three studies have reported
similar findings, two using a glycoarray technique
[4, 5] and another using ELISA [6]. The study by
Galban-Horcajo used a dot blot microarray platform
designed as a screening method for anti-lipid antibod-
ies [7]. In this array, GM1 and GalC were premixed at
a 1:1 weight to weight ratio and this assay returned
a very high sensitivity compared with GM1 alone,
albeit in pre-selected MMN clinical cohort [5]. The
Nobile-Orazio study, following a similar method to
that of Pestronk and co-workers [3] used polystyrene
ELISA plates coated with GM1:GalC in a 1:10 weight
to weight ratio and also showed increased diagnos-
tic sensitivity for MMN [6]. The Delmont study used
a combination of both ELISA and dot blot methods
[4]. Existing studies thus conclude that GalC combined
with GM1 significantly enhance the detection rate and
signal intensity of anti-GM1 Abs, although were not
rigourously controlled for selection bias. The current
study aimed to validate these findings using a large,
unbiased and observer blinded cohort of MMN cases,
ALS cases and healthy controls.
MATERIALS AND METHODS
Sera collection and clinical data
Serum samples from 100 patients with MMN, 100
patients with amyotrophic lateral sclerosis (ALS) and
100 healthy controls (HC) were examined. All par-
ticipants were Dutch caucasians. Diagnostic criteria
for MMN and ALS were applied as published previ-
ously [8, 9]. Muscle strength was recorded in eleven
arm muscle groups and seven leg muscle groups
of patients with MMN using the Medical Research
Council (MRC) scale, and the MRC sum score was
calculated accordingly (maximum 180). Overall dis-
ability was determined using the Overall Disability
Sum Score (ODSS) [10]. Patients underwent nerve
conduction studies following a previously published
[11] protocol. The site of onset (i.e. bulbar, cervical,
thoracic or lumbosacral region) of weakness in patients
with ALS was documented.
Ethical approval was given by the Medical Ethical
Committee of the University Medical Center Utrecht
and all subjects gave written informed consent.
All 300 samples were randomised and coded prior
to commencing the serology screening. The database
was then locked until completion of analysis.
Due to limited volumes of some serum samples,
patients were excluded from experiments with 1:5 and
1:10 GM1:GalC ratios in glycoarray (3 MMN and 3
controls), and from GM1 alone and 1:10 GM1:GalC
in ELISA (4 MMN and 1 control). In such cases,
there was a reduction in the total number of compara-
tive samples for intra- and inter-technique comparison,
which for some lipid antigens, resulted in altering the
sensitivity and specificity (+/- 1%), which was accom-
panied by minor change in the area under the curve
(AUC ≤0.006).
Lipid source and preparation
The glycolipids screened were GM1, GM2, GM3,
GA1, GalC, 3-sulphated galactosylceramide (sul-
phatide, sulph), sulphated glucuronyl paragloboside
(SGPG) and sialosyl-lactoneotetraosylceramide (LM
1). Glycolipids were purchased from Sigma, UK except
SGPG and LM1 which were provided by RK Yu,
Georgia Health Sciences University, USA. Lipid stocks
were dissolved in a 2:1 chloroform/methanol solution.
Then, 1:1 (weight/weight) complexes were created by
mixing equal volumes, at equal concentration, of the
component glycolipid solutions. For the preparation
of 1:5 and 1:10 GM1:GalC complexes, equal volumes
of the two glycolipid solutions were added, although
in this case the GalC solution was 5 and 10 times
respectively more concentrated than the GM1 solution.
ELISA
FortheGM1andGM1:GalC1:10ELISA,theINCAT
method was used [12]. The inclusion of GM1:GalC
1:10 heteromeric complex within this methodology
was performed as previously described and accord-
ing to previously published ratios [5]. Polystyrene
plates (Immulon2HB,Dynatech,UK)werecoatedwith
100 ng of GM1 or 1100 ng of GM1:GalC 1:10 glycol-
ipid(s) in methanol (or methanol alone, blank wells)
and allowed to evaporate. Plates were blocked with 2%
bovine serum albumin (BSA) in phosphate buffered
saline (PBS) for 1 h at 4◦C. Sera were then diluted
in 0.1% BSA/PBS, and 100l applied to duplicate
wells at 1/100 dilution overnight at 4◦C. After washing,
peroxidase-labelled anti-human IgM antibody (diluted
1/3000) was applied for 1 h at 4◦C. Detection was per-
formed with o-phenylenediamine dihydrochloride and
the reaction terminated with 50l of 4 M H2SO4.
Optical density (OD) was detected at 492 nm using an
automated plate reader (SunriseTM, Tecan Group Ltd.,
Ma¨nnedorf, Switzerland).
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Combinatorial glycoarray
Glycoarray was conducted as previously described
[5]. Briefly, 10 ng of single glycolipids or a total weight
of 10, 30 or 55 ng of 1:1, 1:5 or 1:10 heteromeric
glycolipid ratios respectively, were spotted using an
ATS4 TLC autosampler (Camag, Muttenz, Switzer-
land) onto polyvinyldifluoride (PVDF) membranes
affixed to glass slides. Array slides were blocked in
2% BSA/phosphate buffered saline (BSA/PBS), and
then incubated for 1 h at 4◦C with sera diluted 1/100
in 1% BSA/PBS. After washing, rabbit anti-human
IgM horseradish peroxidise conjugated secondary anti-
body (diluted 1:25000) was applied for 30 min at 4◦C.
Binding was detected by enhanced chemiluminescence
(Pierce ECL Plus Western Blotting Substrate, Thermo
scientific, UK). Exposure time was 1 min. Radiographs
were digitized by flatbed scanning, and spot intensity
calculated using TOTALLAB image analysis software
(Nonlinear Dynamics Ltd, Newcastle upon Tyne, UK),
expressed as intensity units (IU).
Statistical analysis
ROC analysis was performed in MEDCALC soft-
ware using Hanley & McNeil methodology. The area
under the curve (AUC) was calculated for each lipid
antigen, and indicated the average diagnostic accuracy
of the test over the entire operating range (threshold-
independent). An area under the curve (AUC) value
of 0.75 was set as the reference cut-off value for a
potentially useful clinical marker, in which a value of
1.0 indicates a perfect test (100% sensitivity, 100%
specificity) and a value of 0.5 corresponds to a random
chance of separating disease from control groups. The
criterion for determining the optimal threshold value,
for categorising samples as healthy or diseased, was
calculated using Youden index (J) (MEDCALC). This
value equates to the point on the ROC curve with maxi-
mum difference between sensitivity (true positive rate)
and 100-specificity (false positive rate). Comparisons
of technique or lipid antigen and their correspond-
ing sensitivity and specificity were performed using
the McNemar Chi-squared test [13]. Intensity unit
values for glycoarrays were used to produce heat
maps and were clustered relative to GM1 intensity
(MEV software; Dana-Farber Cancer Institute, Boston,
MA, USA). All the remaining graphic representa-
tions were produced using GRAPHPAD PRISM 6
software (GraphPad Software Inc., San Diego, CA,
USA).
RESULTS
ROC analysis of glycoarray data
Glycoarray binding profiles, from which the
quantitative data are derived, illustrate the typical
enhancement of binding to GM1 by GalC (Fig. 1a, b).
From these raw data, heat maps were generated, here
illustrated for GM1, GM2 and GA1 in complex with
GalC and alone (Fig. 1c). GM1:GalC 1:1 was the best
performing marker for discriminating MMN from both
ALS and HC, yielding a value of 0.834 (Table 1).
Next, GM1:GalC 1:5 and GM1 alone presented AUCs
of 0.777 and 0.764 respectively. The AUC differ-
ence between GM1:GalC 1:1 and GM1 alone was
significant (0.834 vs 0.764, P = 0.005).). For GM2
and GM2:GalC, antibody binding events are less pro-
nounced overall in all groups but slightly favour MMN,
and also appears to be scattered independently of anti-
GM1 intensity. For GA1 and GA1:GalC, a relative
increase in positive sera is again seen in the MMN
group that partly co-segregates in intensity with the
anti-GM1 signal intensity; however both the HC and
ALS cohorts also show high binding frequency to both
GA1 and GA1:GalC. All the glycoarray data for all
300 samples were then subjected to ROC analysis in
order to quantitatively assess the diagnostic accuracy
obtained using different lipid targets. AUCs were then
calculated from the ROC curves. Fig. 1d shows the
ROC curves for the six targets shown in the heatmap.
Other ROC curves are not shown, but extracted data is
tabulated as described below. Other than GM1:SGPG,
yielding an AUC of 0.760, no other marker under
scrutiny, including both GM2 and GA1, fell above the
threshold of acceptance (0.75) for a clinically useful
marker.
When analysing the two different groups of con-
trols (ALS and HC) as separate categories, GM1:GalC
Table 1
Test performance of glycoarray and ELISA for GM1 alone and
GM1:GalC at the various ratios after cut-off value optimisation
Cut-off criterion Sensitivity Specificity AUC
value∗
Glycoarray
GM1 >5325 67 85 0.764
GM1:GalC 1:1 >0 81 80 0.834
GM1:GalC 1:5 >14650 70 77 0.778
GM1:GalC 1:10 >21280 61 79 0.743
ELISA
GM1 >0.19 49 91 0.749
GM1:GalC 1:10 >0.12 69 74 0.767
∗Cut-off value optimised for the highest diagnostic accuracy as deter-
mined by the J-index
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Fig. 1. Panel a. Glycoarray grids illustrating that antibody binding to GM1 is enhanced by the presence of GalC. Panel b. Samples sero-negative
for GM1 alone are antibody positive at increasing ratios of GM1:GalC. Panel c. Heat map illustration of all 300 serum samples tested by
glycoarray. Each sample is colour coded according to the intensity of binding to each target (red represents the strongest down through the
rainbow scale to blue which is weakest and black equals no binding), and data has been sorted by decreasing GM1:GalC intensity in the 3
clinical categories (left to right, top row). Each sample in subsequent vertical column is locked to the intensity order assigned by the top row.
Visual inspection of the heat map clearly indicates the positive bias towards GM1:GalC and GM1 binding in the MMN population compared
with HC and ALS. Panel d. ROC curve plotting sensitivity against 100-specificity of selective lipid markers tested on glycoarray. For each lipid
target, an area under the curve (AUC) is calculated, in which the best lipid marker will have an AUC closest to 1. In this example GM1:GalC
1:1 (AUC = 0.834) is determined to be the best discriminator of MMN and control serum samples, and was found to be statistically significant
from the second most efficient lipid, GM1 alone (AUC = 0.764, P = 0.0051).
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1:1 still yields a significantly better diagnostic perfor-
mance than GM1 alone. Thus, comparing the MMN
group against the ALS group yields an AUC of 0.787
for GM1 and 0.858 for GM1:GalC 1:1 (P = 0.009).
The same analysis for MMN versus HC yields an
AUC of 0.741 for GM1 and 0.809 for GM1:GalC 1:1
(P = 0.012).
Comparative evaluation by glycoarray of GM1
and GM1:GalC ratios
The intensity threshold to best define healthy con-
trols from patients was calculated from the ROC
analysis curves for each lipid target (Table 1), and the
ability of the assay to correctly categorise samples as
MMN (sensitivity) or controls (specificity) was thereby
compared at optimal assay thresholds (Table 2). Across
all disease and control categories, increasing the ratio
of GalC relative to GM1 in the GalC:GM1 complexes
resulted in an overall increase in antibody binding
intensities, (as illustrated in Fig. 1a,b). This increase
included anti-GM1 positive MMN and control sam-
ples, and those found to be seronegative for GM1.
To compensate for this overall increase in antibody
binding with an increasing GalC ratio, threshold cut
off values (automatically assigned in the ROC analy-
sis) increased, in order to most favourably delineate
healthy and control populations. Only in the case of
GM1:GalC 1:1 was the threshold reduced (to zero)
compared with the threshold for GM1 (5325 units);
a contributing factor being that GM1:GalC complexes
contained half as much GM1 lipid antigen (5 ng) as that
applied per spot in GM1 alone (10 ng). The addition of
GalC to GM1 in a 1:1 ratio yielded a statistically signif-
icant improvement in the glycoarray sensitivity (from
67% to 81%, P = 0.003) without a significant loss of
specificity (falling from 85% to 80%, P = 0.064), when
compared with the current gold standard of GM1 alone
(Table 2).
Increasing the ratio of GM1:GalC to 1:5 or 1:10,
compared with GM1, did not further improve the assay
sensitivity and indeed resulted in a significant reduc-
tion in specificity. Increasing the GM1:GalC ratio to
1:10 resulted in a sensitivity significantly worse than
either 1:1 or 1:5 (P = 0.001 and P = 0.013 respectively).
The assay performance of GM1:GalC 1:1 and 1:5
were broadly similar (sensitivity p = 0.078 and speci-
ficity P = 0.233), however as a ratio of 1:5 was not
a significant improvement over GM1 alone and both
sensitivity and specificity were reduced (albeit, not sig-
nificantly) compared to a ratio of 1:1, it was concluded
that the most suitable lipid target, in this study, for cor-
Table 2
Clinical characteristics of GM1:GalC positive and negative MMN
patients
GM1:GalC reactivity P-value
Negative Positive
Number 19 81
Gender, male 15 (79) 58 (72) 0.52
Age at onset 41 (22–52) 42 (22–68) 0.40
Site of onset
Cervical 12 (63) 57 (70) 0.54
Lumbar 7 (37) 24 (30)
MRC sum score 170 (128–179) 164 (113–179) 0.08
ODSS 3 (2–6) 3 (1–9) 0.39
Conduction block
Definite 16 (84) 68 (84) 0.98
Probable 3 (16) 13 (16)
Degree axon lossa 2 (0–8) 2 (0–9) 0.55
On IVIg maintenance 14 (74) 64 (79) 0.61
treatment
Data are median (range) or number (%). Abbreviations:
ODSS = Overall Disability Sum Score. aNumber of nerves with
decreased distal compound muscle action potential (maximum 12).
rectly assigning MMN patients as anti-GM1 antibody
positive (and control groups as anti-GM1 antibody
negative) on glycoarray was GM1:GalC 1:1. The com-
bination of GM1 alone and/or GM1:GalC 1:1 yields a
sensitivity of 84% (84/100; 64 positive for both, 3 pos-
itive for GM1 alone and 17 positive for GM1:GalC
1:1 alone) and a specificity of 78% (155/200).
These data are tabulated in a flow chart for clarity
(Fig. 2).
Fig. 2. Flow chart diagram illustrating categorisation of all 300
serum samples tested by glycoarray as positive (>threshold) or
negative (≤threshold) for GM1 (threshold = 5325) and GM1:GalC
(threshold = 0). For all samples considered negative for both GM1
and GM1:GalC 1:1, the samples were also categorised according
to ‘other reactivities’, in which a positive sample is determined as
being greater than the calculated threshold for any lipid target tested
on glycoarray.
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Comparative evaluation by ELISA of GM1 alone
and GM1:GalC 1:10
ELISA assays were performed using GM1 alone
and GM1:GalC at the 1:10 ratio previously used in
other studies, and optimal threshold values were cal-
culated for each target (Table 2). Insufficient sample
volumes were available to perform the study at multi-
ple GM1:GalC ratios by ELISA (see methods section).
For GM1 alone, applying a threshold of OD >0.19,
the assay yielded 51% sensitivity and 91% specificity.
When GalC was added in a ratio of 1:10, applying an
optimal threshold of OD >0.12, the sensitivity signif-
icantly increased to 70% (P = 0.0001). However, this
was accompanied by a significant reduction in speci-
ficity to 74% (P < 0.0001). When specific thresholds
were selected to classify healthy and disease groups,
neither lipid antigen resulted in a clear advantage when
weighing up assay performance by both sensitivity and
specificity. We then assessed the average accuracy of
GM1 alone and GM1:GalC 1:10 across all measured
values (AUC = 0.752 and 0.769 respectively), and once
more, no significant difference was found (P = 0.541),
suggesting that both lipid coatings on ELISA per-
formed equally.
Comparative analysis of ELISA and glycoarray
data
ELISA and glycoarray techniques were compared
using defined sample sets for each lipid antigen, and
threshold values previously optimised for each assay
(Table 1). For GM1:GalC 1:10, the glycoarray and
the ELISA performed similarly (sensitivity = 61% vs
69%,P = 0.23 and specificity = 79% vs 74%,P = 0.253,
respectively). These data are also presented in box
and whisker plots with outliers (Fig. 3) for ease of
comparison, where it is clearly evident that whilst the
MMN group harbours a greater proportion of higher
intensity samples when assayed by either glycoar-
ray or ELISA, considerable categorical overlap exists
at this 1:10 GM1:GalC ratio. In particular, there are
an equal number of rare individual samples in all
three groups (MMN, ALS and HC) in which anti-
body signals are very high, lying beyond the limit of
the upper interquartile range (i.e. outliers, plotted as
individual dots), when assayed by either ELISA or
glycoarray.
For GM1 alone, sensitivity was significantly bet-
ter in the glycoarray than the ELISA (67% vs 51%,
P = 0.004). Thus for GM1 alone, 20 ELISA-negative
MMN patients were positive on glycoarray, whereas
a b
Fig. 3. Box and whisker plots graphically illustrating the median and inter quartile data range for antibody binding intensity (glycoarray) and
optical density (ELISA) for all 3 sample categories for GM1:GalC at 1:10 ratio. Outliers are individually assigned a data point (filled black circle) a.
When testing by glycoarray a threshold of 21280 (dotted line) is applied to optimally discriminate disease and healthy groups. Complete separation
of these groups is not possible, due to a substantial number of the control groups that were measured with binding intensities above the threshold. b.
It is a similar scenario for ELISA utilising an optimised threshold of 0.121 (dotted line). When GalC is applied to GM1 at increasing ratios, antibody
binding is increased in both MMN and control groups, thereby reducing both sensitivity and specificity compared with the optimal 1:1 ratio of
GM1:GalC.
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only 5 glycoarray-negative MMN patients were posi-
tive on ELISA. The improved sensitivity of glycoarray
was at the expense of reduced specificity when
compared with ELISA (84% vs 91% P = 0.031).
The increase in the diagnostic false positive sam-
pling rate resulted from 22 ELISA-negative controls
being positive on glycoarray, in comparison with 9
glycoarray-negative controls being positive on ELISA.
In addition, a further 9/199 controls (5%) were cate-
gorised as positive in both techniques, at these specific
cut-off values.
Correlation analysis conducted to compare GM1
and GM1:GalC 1:10 ELISA and glycoarray values
in any one sample returned correlation coefficients
of 0.58 and 0.45 respectively, indicating weak intra-
sample concordance across the two techniques, even
through overall sensitivity and specificity data were
similar.
As there was no statistically clear advantage
between techniques at optimal threshold, we compared
the average accuracy of glycoarray and ELISA using
GM1 alone across all measured values (AUC = 0.762
and 0.752 respectively), and once more, no significant
difference was found (P = 0.784), suggesting that both
techniques performed equally when the GM1:GalC
ratio was set at 1:10. Since the ELISA was only con-
ducted at a GM1:GalC ratio of 1:10, it is not possible
to directly compare both methods at 1:1 ratios. How-
ever, when comparing the optimally performing array
conditions of GM1:GalC 1:1 with the GM1:GalC 1:10
ELISA, improvements in sensitivity (80% vs 70%) and
specificity (80% vs 74%) were seen, although these did
not achieve statistical significance (P = 0.09 and 0.12
respectively).
Association with clinical characteristics
The clinical characteristics of GM1:GalC Ab posi-
tive and negative MMN patients are depicted in Table 2.
None of the clinical features were significantly dif-
ferent between the two patient groups, although the
GM1:GalC positive patients tended to have more pro-
nounced weakness (MRC sum score 164 vs. 170,
p = 0.08), in keeping with previous findings [14]. The
clinical features of the 17 GM1:GalC positive ALS
patients were compared with the antibody negative
ALS patients. There was no difference in gender,
age at onset, site of onset or upper and lower motor
neuron involvement on neurological examination. Fur-
thermore, disease duration and mortality were similar
(2.9 vs. 2.8 years p = 0.45 and 88% vs. 90% p = 0.79,
respectively).
DISCUSSION
Herein we demonstrate that the addition of GalC
to GM1 improves the diagnostic sensitivity of anti-
GM1 IgM Ab detection in patients with MMN relative
to healthy control and ALS cases, using both glycoar-
ray and ELISA measurement techniques. Our previous
studies using glycoarray [5], and a recent study using
ELISA [6] have already reinforced the previous find-
ings that GM1 and GalC in complex generate an Ab
binding enhancing effect [3]. The distinctive feature of
the current study is that it adopts a fully blinded design
to test a relatively large number of samples for the
effect of GM1-GalC complexes on test characteristics
in a diagnostic laboratory independent of the source of
clinical material.
Our data indicate that using GalC-GM1 complexes
at 1:1 (weight to weight) ratio in glycoarray sig-
nificantly improves the IgM Ab detection rate (i.e.
diagnostic sensitivity), without significantly altering
specificity. Further ratiometric increases of GalC up
to 1:5 and 1:10 weight to weight ratios relative to
GM1 significantly decreased specificity, particularly
at the higher ratio of GalC, without any concomitant
improvement in sensitivity, and should thus be avoided
when designing these assays for clinical diagnostic use.
The effect of increasing GalC on reducing specificity
appeared more pronounced in ELISA than in glycoar-
ray, but owing to the limited range of GM1:GalC ratios
used in ELISA, definite conclusions on the optimal
configuration of the ELISA cannot be drawn from this
study. In particular, it remains possible that lower GalC
ratios and/or introduction of additional lipids such as
neutral lipids or cholesterol might yield different sen-
sitivity and specificity data, using either ELISA or
glycoarray. However since this study was designed as
a validation study of existing reported ratios, further
exploration of these variations was not performed.
Although both ELISA and glycoarray register the
same phenomenon of GalC-dependent enhancement of
anti-GM1 Ab binding, correlation between both their
binding intensity levels (i.e. titre or amount) and their
diagnostic performances (i.e. positive or negative) with
any one sample was inexact. At a given intensity and
OD threshold, both techniques returned similar diag-
nostic scores when considering the sample groups as
a whole, with no difference in either sensitivity or
specificity. However, individual samples might yield
positive results by glycoarray and negative results by
ELISA, and vice versa, as borne out by the low corre-
lation coefficients (∼0.5) in regression analysis. This
is likely due to clinical samples containing a highly
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diverse collection of heterogeneous anti-GM1 antibod-
ies of slightly differing specificity and affinity/avidity
for the GM1 oligosaccharide. The 2 techniques detect
these binding events to varying extents according to
the antigen conformation adopted on adherence to the
assay surfaces (polystyrene or PVDF) that are biophys-
ically distinct, as has been previously suggested [15].
This does not indicate methodological imprecision, but
rathermore, methodological differences. Practically,
however, this may confound clinical interpretation
since one assay method may produce a positive result
on an individual sample that is not recapitulated in a
second assay.
In diagnostic testing, it is essential to recognise
that the healthy population may possess circulating
antibodies with a similar binding profile to the dis-
ease category under investigation, as is very evidently
the case for anti-GM1 IgM antibodies. Indeed, all
anti-glycolipid antibodies vary in their baseline levels
within the normal population, which may be related to
ethnicity and geographical location. The selection of
robust and appropriate control groups is thus a criti-
cal factor in assay development. Some anti-glycolipid
antibodies, such as anti-GD1a and -GQ1b IgG antibod-
ies, may be so rarely present in the normal population
that they represent good biomarkers. In contrast anti-
GA1 and anti-sulfatide antibodies are very commonly
found, and thus require the establishment of different
assay parameters. In such cases, a clear separation of
healthy from disease groups is not possible. Applica-
tion of a cut-off may enable detection of all of the dis-
ease patients, however, if the selected threshold value
encroaches upon the upper limit of normal in the con-
trol samples, there will be a reduction in specificity, and
a corresponding increase in diagnostic false positives.
This scenario is commonly seen with anti-glycolipid
diagnostic assays, and this highlights the reciprocal
relationship between sensitivity and specificity.
Whilst it is clear that anti-GM1 and -GM1:GalC
IgM antibodies are expanded in MMN relative to nor-
mal and disease controls, it is pertinent to ask whether
this biomarker has sufficient accuracy to be useful in
clinical diagnostics, using either ELISA or glycoarray
methods. In a small disease cohort examined under
strictly controlled laboratory parameters combined
with patient referral bias, such as observed in our recent
MMN study [5], it was possible to segregate all MMN
patients (100% sensitivity) with minimal detection of
diagnostic false positives (4/57, 93% specificity). As
the sample size, clinical referral pattern and assay
diversity increases, this becomes increasingly difficult
to achieve. Thus, if 1000 unselected neuropathy cases
seen in routine clinical practice are all referred for anti-
GM1 IgM antibody testing, and one assumes an MMN
frequency of 0.5% of all neuropathies and an assay
sensitivity of 80% and specificity of 80%, then 203
patients will yield a positive anti-GM1 IgM antibody
assay result, only 4 of whom will have MMN. Even in
specialized motor neuron disease clinics where asym-
metric weakness is a common phenotype and where
MMN frequency may be tenfold higher (5%), the vast
majority of patients with anti-GM1 antibodies will
have MND. This underlines the importance of under-
standing patient selection criteria in laboratory testing
settings.
The finding of IgM antibodies to GM1:GalC in
MMN patients previously described as antibody nega-
tive which showed no differences in disease phenotype
when compared to antibody positive patients, strength-
ens once again the notion of MMN as an antibody
driven neuropathy. The elusive antibody presumed to
be present in ‘antibody-negative’ cases remains to be
identified. Alternatively the anti-GM1 antibody we
measure in serum represents a benign antibody pop-
ulation that frequently but not always co-segregates
with a separate population of neurotoxic antibodies
whose detection methodology and specificity remains
to be determined. This latter view would be consis-
tent with the substantial overlap in finding apparently
benign anti-GM1 IgM antibodies in normal and disease
control populations.
The pathogenic roles, if any, of anti-GM1:GalC
antibodies remain to be explored, although it might
be predicted that they would favour the targeting of
GM1 in myelin membranes (since GalC is a myelin
lipid) rather than GM1 in axolemmal membranes. The
findings of substantially elevated antibody levels in a
proportion of healthy control and ALS groups suggests
that their neurotoxicity may be limited to very specific,
as yet poorly understood immunopathological circum-
stances. With respect to the origin of anti-GM1:GalC
antibodies, they may arise from the innate immune
repertoire or arise through antigen-driven pathways;
this remains to be investigated.
In clinical diagnostic practice, the GM1:GalC 1:1
assay improves sensitivity without significantly affect-
ing specificity and could readily be introduced into
ELISA or dot blot assay formats for use in routine test-
ing. Inter-laboratory variation in methods, including
commercially-available kits, dictates that GM1:GalC
ratios should be optimised in a range-finding study at
an individual laboratory or kit manufacturer level.
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